Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr

Dr Reddy's Q2 performance sees revenue boost, but challenges persist
Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong 16.5 percent year-on-year rise, slightly exceeding the estimate of Rs 7,854 crore.
Dr Reddys Laboratories Q2 Results Live: Profit Falls by 15.28% YoY
Dr Reddys Laboratories Q2 Results Live : Dr Reddys Laboratories announced its Q2 results on November 5, 2024, revealing a mixed performance. The company's topline saw a significant increase of 16.45% year-over-year, yet profit fell by 15.28%, indicating challenges in maintaining profitability despite higher revenues.
Dr Reddy's Labs shares in focus after Q2 profit falls 15% YoY. What should investors do?
Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock's future prospects,
Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%
Dr Reddy's Lab’s average revenue will potentially increase 12 per cent Y-o-Y to Rs 7,734 crore as against Rs 6,902 crore in Q2FY24. On a quarterly basis, the revenues may rise by 0.4 per cent. The pharma company registered revenues of Rs 7,696 crore in the June quarter of FY25.
Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
ndtvprofit2h
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
Business Insider17h
Dr. Reddy’s Laboratories Reports Q2 Revenue Growth
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by ...
cnbctv183h
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Shares of Dr. Reddy's Laboratories Ltd. will be closely watched in Wednesday's trading as its revenue for the September ...
Dr Reddy’s clocks 16.51% increase in Q2 revenues
New Delhi: Pharma major Dr Reddy’s Laboratories (DRL ... Its total operating expenses grew 34.3 per cent to Rs3,021.8 ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...